Androgens and prostate disease

Asian Journal of Andrology

Volumn 16, Issue 2, 2014, Pages 248-255

  Cooper, Lori A ^a   Page, Stephanie T ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Androgens; Male hypogonadism; Prostate; Testosterone

Indexed keywords

ABIRATERONE; ANDROGEN; ANDROSTANEDIOL; ANDROSTANOLONE; ANDROSTENEDIONE; DUTASTERIDE; ESTRADIOL; FINASTERIDE; GONADORELIN AGONIST; PRASTERONE SULFATE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; TESTOSTERONE ENANTATE;

ABSENCE OF SIDE EFFECTS; AGING; ANDROGEN BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; ANDROGEN PROSTATE LEVEL; ANDROGEN THERAPY; BONE MASS; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG EFFECT; HUMAN; HYPOGONADISM; LOWER URINARY TRACT SYMPTOM; MALE; MUSCLE STRENGTH; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; PROSTATE VOLUME; REVIEW; RISK FACTOR; SEXUAL FUNCTION; TESTOSTERONE BLOOD LEVEL; TISSUE LEVEL;

ANDROGENS; HUMANS; MALE; PROSTATIC DISEASES; PROSTATIC NEOPLASMS;

EID: 84896755976     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.4103/1008-682X.122361     Document Type: Review

References (104)

1. Freeman ER, Bloom DA, McGuire EJ. A brief history of testosterone. J Urol 2001;165: 371-3. (Pubitemid 32060415)
2. Gan EH, Pattman S, H S Pearce S, Quinton R. A UK epidemic of testosterone prescribing, 2001-2010. Clin Endocrinol (Oxf) 2013;79: 564-70.
3. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001;86: 724-31. (Pubitemid 32207487)
4. Travison TG, Araujo AB, Kupelian V, O'Donnell AB, McKinlay JB. The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab 2007;92: 549-55.
5. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95: 2536-59.
6. Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 2004;89: 534-43. (Pubitemid 38269854)
7. CDC - Laboratory Quality Assurance and Standardization Programs. http://www.cdc. gov/labstandards/hs.html. [Last accessed 2013 Nov 1].
8. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, et al. EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010;363: 123-35.
9. Araujo AB, Esche GR, Kupelian V, O'Donnell AB, Travison TG, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007;92: 4241-7. (Pubitemid 350074738)
10. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999;84: 2647-53. (Pubitemid 30641987)
11. Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 2005;90: 1502-10. (Pubitemid 40464011)
12. Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004;89: 503-10. (Pubitemid 38269849)
13. Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf) 2005;63: 381-94. (Pubitemid 41442332)
14. Gray PB, Singh AB, Woodhouse LJ, Storer TW, Casaburi R, et al. Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men. J Clin Endocrinol Metab 2005;90: 3838-46. (Pubitemid 41058141)
15. Joshi D, van Schoor NM, de Ronde W, Schaap LA, Comijs HC, et al. Low free testosterone levels are associated with prevalence and incidence of depressive symptoms in older men. Clin Endocrinol (Oxf) 2010;72: 232-40.
16. Shores MM, Sloan KL, Matsumoto AM, Moceri VM, Felker B, et al. Increased incidence of diagnosed depressive illness in hypogonadal older men. Arch Gen Psychiatry 2004;61: 162-7. (Pubitemid 38146550)
17. Moffat SD, Zonderman AB, Metter EJ, Blackman MR, Harman SM, et al. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab 2002;87: 5001-7. (Pubitemid 35316338)
18. Shores MM, Kivlahan DR, Sadak TI, Li EJ, Matsumoto AM. A randomized, double-blind, placebo-controlled study of testosterone treatment in hypogonadal older men with subthreshold depression (dysthymia or minor depression). J Clin Psychiatry 2009;70: 1009-16.
19. Seidman SN, Orr G, Raviv G, Levi R, Roose SP, et al. Effects of testosterone replacement in middle-aged men with dysthymia: a randomized, placebo-controlled clinical trial. J Clin Psychopharmacol 2009;29: 216-21.
20. Srinivas-Shankar U, Roberts SA, Connolly MJ, O'Connell MD, Adams JE, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010;95: 639-50.
21. O'Connell MD, Roberts SA, Srinivas-Shankar U, Tajar A, Connolly MJ, et al. Do the effects of testosterone on muscle strength, physical function, body composition, and quality of life persist six months after treatment in intermediate-frail and frail elderly men? J Clin Endocrinol Metab 2011;96: 454-8.
22. Behre HM, Tammela TL, Arver S, Tolra JR, Bonifacio V, et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male 2012;15: 198-207.
23. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008;93: 68-75.
24. Cawthon PM, Ensrud KE, Laughlin GA, Cauley JA, Dam TT, et al. Osteoporotic Fractures in Men (MrOS) Research Group. Sex hormones and frailty in older men: the osteoporotic fractures in men (MrOS) study. J Clin Endocrinol Metab 2009;94: 3806-15.
25. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006;166: 1660-5. (Pubitemid 44232378)
26. Maggio M, Lauretani F, Ceda GP, Bandinelli S, Ling SM, et al. Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study. Arch Intern Med 2007;167: 2249-54. (Pubitemid 350106746)
27. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab 2012;97: 2050-8.
28. Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010;95: 2560-75.
29. Sandblom RE, Matsumoto AM, Schoene RB, Lee KA, Giblin EC, et al. Obstructive sleep apnea syndrome induced by testosterone administration. N Engl J Med 1983;308: 508-10. (Pubitemid 13195480)
30. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, et al. Adverse events associated with testosterone administration. N Engl J Med 2010;363: 109-22.
31. Gan EH, Pattman S, H S Pearce S, Quinton R. A UK epidemic of testosterone prescribing, 2001-2010. Clin Endocrinol (Oxf) 2013; 79: 564-70. doi:10.1111/cen.12178. Epub 2013 Apr 5.
32. George FW and Wilson JD. Sex Determination and Differentiation. In: E. Knobil and J. Neil, Eds., Physiology of Reproduction, 2nd Edition, Raven Press, New York, 1994, p. 3-28.
33. Andriole G, Bruchovsky N, Chung LW, Matsumoto AM, Rittmaster R, et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 2004;172: 1399-403. (Pubitemid 39249729)
34. Steers WD. 5alpha-reductase activity in the prostate. Urology 2001;58: 17-24.
35. Cunha GR, Hayward SW, Wang YZ. Role of stroma in carcinogenesis of the prostate. Differentiation 2002;70: 473-85. (Pubitemid 36194313)
36. Huggins CH. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1: 293-7.
37. Morgentaler A. Testosterone therapy in men with prostate cancer: scientific and ethical considerations. J Urol 2013;189:S26-33.
38. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol 2006;50: 935-9. (Pubitemid 44486489)
39. Morgentaler A, Bruning CO 3rd, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA 1996;276: 1904-6. (Pubitemid 26419188)
40. Fowler JE Jr, Whitmore WF Jr. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 1981;126: 372-5. (Pubitemid 11061000)
41. Morales A. Testosterone and prostate health: Debunking myths demands evidence, caution, and good clinical judgment. Eur Urol 2006;50: 895-7. (Pubitemid 44486488)
42. Rhoden EL, Morgentaler A. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol 2003;170: 2348-51. (Pubitemid 37413994)
43. Morgentaler A, Lipshultz LI, Bennett R, Sweeney M, Avila D Jr, et al. Testosterone therapy in men with untreated prostate cancer. J Urol 2011;185: 1256-60.
44. Leibowitz RL, Dorff TB, Tucker S, Symanowski J, Vogelzang NJ. Testosterone replacement in prostate cancer survivors with hypogonadal symptoms. BJU Int 2010;105: 1397-401.
45. Pastuszak AW, Pearlman AM, Lai WS, Godoy G, Sathyamoorthy K, et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol 2013;190: 639-44.
46. Pastuszak AW, Pearlman AM, Godoy G, Miles BJ, Lipshultz LI, et al. Testosterone replacement therapy in the setting of prostate cancer treated with radiation. Int J Impot Res 2013;25: 24-8.
47. Parsons JK, Carter HB, Platz EA, Wright EJ, Landis P, et al. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev 2005;14: 2257-60. (Pubitemid 41603276)
48. Pierorazio PM, Ferrucci L, Kettermann A, Longo DL, Metter EJ, et al. Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging. BJU Int 2010;105: 824-9.
49. Trifiro MD, Parsons JK, Palazzi-Churas K, Bergstrom J, Lakin C, et al. Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men. BJU Int 2010;105: 1554-9.
50. Parsons JK, Palazzi-Churas K, Bergstrom J, Barrett-Connor E. Prospective study of serum dihydrotestosterone and subsequent risk of benign prostatic hyperplasia in community dwelling men: The Rancho Bernardo Study. J Urol 2010;184: 1040-4.
51. Severi G, Morris HA, MacInnis RJ, English DR, Tilley W, et al. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15: 86-91.
52. Heikkila R, Aho K, Heliovaara M, Hakama M, Marniemi J, et al. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study. Cancer 1999;86: 312-5. (Pubitemid 29327588)
53. Endogenous Hormones and Prostate Cancer Collaborative Group, Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: A collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008;100: 170-83. (Pubitemid 351480553)
54. Carpenter WR, Robinson WR, Godley PA. Getting over testosterone: Postulating a fresh start for etiologic studies of prostate cancer. J Natl Cancer Inst 2008;100: 158-9. (Pubitemid 351480558)
55. Clark R. Can the risk of prostate cancer be reduced? In: 91st Annual Meeting of the Endocrine Society. Washington DC; 2009.
56. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349: 215-24. (Pubitemid 36859473)
57. Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol (Oxf) 1994;40: 341-9. (Pubitemid 24194627)
58. Gerstenbluth RE, Maniam PN, Corty EW, Seftel AD. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement. J Androl 2002;23: 922-6. (Pubitemid 36300984)
59. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Mac RP, et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab 2005;90: 678-88. (Pubitemid 40279179)
60. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005;60: 1451-7. (Pubitemid 41798454)
61. Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, et al. Early detection of prostate cancer: AUA Guideline. J Urol 2013;190: 419-26.
62. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, et al. PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360: 1310-9.
63. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, et al. ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360: 1320-8.
64. The testosterone trial in older men. http://clinicaltrials.gov/show/ NCT00799617. ClinicalTrials.gov identifier: NCT00799617. [Last accessed on 2013 July 24].
65. Jin B, Turner L, Walters WA, Handelsman DJ. The effects of chronic high dose androgen or estrogen treatment on the human prostate [corrected]. J Clin Endocrinol Metab 1996;81: 4290-5.
66. Cooper CS, MacIndoe JH, Perry PJ, Yates WR, Williams RD. The effect of exogenous testosterone on total and free prostate specific antigen levels in healthy young men. J Urol 1996;156: 438-41.
67. Pallais JC, Morgentaler A, Barry CV, Hahn CW, Finkelstein JS. Dose-response relationship between testosterone and prostate specific antigen in healthy men [abstract]. Presented at: endocrine Society annual meeting; Washington, DC; June 10-13, 2009. Abstract OR42-4.
68. Finkelstein JS. Toward a physiologic definition of male hypogonadism: how much testosterone does a man really need [abstract]? Presented at: Endocrine Society annual meeting; Washington, DC; June 10-13, 2009. Abstract S60-3.
69. Page ST, Hirano L, Gilchriest J, Dighe M, Amory JK, et al. Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy. J Urol 2011;186: 191-7.
70. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, et al. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest 1993;92: 903-10. (Pubitemid 23262413)
71. Silver RI, Wiley EL, Thigpen AE, Guileyardo JM, McConnell JD, et al. Cell type specific expression of steroid 5 alpha-reductase 2. J Urol 1994;152: 438-42. (Pubitemid 24221239)
72. Kazutoshi Y, Labrie F, Luu-The V. Characterization of a new type 3 5α-reductase, an enzyme involves in the biosynthesis of dihydrotestosterone, highly expressed in skin, mammary glands, breast cancer cell lines and adipose tissue, and inhibited by Finasteride. In: 91st Annual Meeting of the Endocrine Society. Washington, DC; 2009.
73. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 2004;89: 2179-84. (Pubitemid 38619850)
74. Amory JK, Wang C, Swerdloff RS, Anawalt BD, Matsumoto AM, et al. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab 2007;92: 1659-65. (Pubitemid 46997168)
75. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992;327: 1185-91.
76. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998;338: 557-63. (Pubitemid 28114643)
77. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. ARIA3001 ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60: 434-41. (Pubitemid 35292169)
78. Roehrborn CG, Nickel JC, Andriole GL, Gagnier RP, Black L, et al. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the Reduction by Dutasteride of prostate Cancer Events (REDUCE) trial. Urology 2011;78: 641-6.
79. Marberger M. Drug insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia. Nat Clin Pract Urol 2006;3: 495-503. (Pubitemid 44377540)
80. Cohen YC, Liu KS, Heyden NL, Carides AD, Anderson KM, et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99: 1366-74. (Pubitemid 351767189)
81. Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99: 1375-83. (Pubitemid 351767184)
82. Ross RK, Skinner E, Cote RJ. Prevention of prostate cancer with finasteride. N Engl J Med 2003;349: 1569-72.
83. Scardino PT. The prevention of prostate cancer - the dilemma continues. N Engl J Med 2003;349: 297-9. (Pubitemid 36859482)
84. Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004;172: 1314-7. (Pubitemid 39249705)
85. Andriole GL, Humphrey P, Ray P, Gleave ME, Trachtenberg J, et al. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol 2004;172: 915-9. (Pubitemid 39096422)
86. Iczkowski KA, Qiu J, Qian J, Somerville MC, Rittmaster RS, et al. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. Urology 2005;65: 76-82. (Pubitemid 40169609)
87. Bhasin S, Travison TG, Storer TW, Lakshman K, Kaushik M, et al. Effect of testosterone supplementation with and without a dual 5alpha-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial. JAMA 2012;307: 931-9.
88. Marks LS, Hess DL, Dorey FJ, Luz Macairan M, Cruz Santos PB, et al. Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens. Urology 2001;57: 999-1005. (Pubitemid 32405333)
89. McConnell JD, Wilson JD, George FW, Geller J, Pappas F, et al. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992;74: 505-8.
90. Norman RW, Coakes KE, Wright AS, Rittmaster RS. Androgen metabolism in men receiving finasteride before prostatectomy. J Urol 1993;150: 1736-9. (Pubitemid 24346938)
91. Rittmaster R, Hahn RG, Ray P, Shannon JB, Wurzel R. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer. Urology 2008;72: 808-12.
92. Page ST, Lin DW, Mostaghel EA, Hess DL, True LD, et al. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 2006;91: 3850-6. (Pubitemid 44536854)
93. Mohler JL, Gregory CW, Ford OH 3rd, Kim D, Weaver CM, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10: 440-8. (Pubitemid 38173980)
94. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68: 4447-54.
95. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 2006;296: 2351-61. (Pubitemid 44749363)
96. Page ST, Lin DW, Mostaghel EA, Marck BT, Wright JL, et al. Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial. J Clin Endocrinol Metab 2011;96: 430-7.
97. Luu-The V, Belanger A, Labrie F. Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrinol Metab 2008;22: 207-21. (Pubitemid 351611954)
98. Chang KH, Li R, Papari-Zareei M, Watumull L, Zhao YD, et al. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci U S A 2011;108: 13728-33.
99. Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 2011;17: 5913-25.
100. Banerjee PP, Banerjee S, Dorsey R, Zirkin BR, Brown TR. Age-.and lobe-specific responses of the brown Norway rat prostate to androgen. Biol Reprod 1994;51: 675-84. (Pubitemid 24284400)
101. Berry SJ, Isaacs JT. Comparative aspects of prostatic growth and androgen metabolism with aging in the dog versus the rat. Endocrinology 1984;114: 511-20. (Pubitemid 14183252)
102. Wright AS, Douglas RC, Thomas LN, Lazier CB, Rittmaster RS. Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase. Endocrinology 1999;140: 4509-15. (Pubitemid 30666115)
103. Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 2009;55: 310-20.
104. Isbarn H, Pinthus JH, Marks LS, Montorsi F, Morales A, et al. Testosterone and prostate cancer: revisiting old paradigms. Eur Urol 2009;56: 48-56.